Ankylosing Spondylitis News and Research

RSS
Ankylosing Spondylitis (AS) is a painful and progressive form of spinal arthritis and symptoms of inflammatory back pain often first present in people before age 35. It typically begins in the late teens and early twenties and in severe cases may result in fusing spinal vertebrae and may cause structural damage to hips and other joints. Often misdiagnosed as "just back pain" or undifferentiated arthritis, AS is a systemic inflammatory disease that, in addition to its effect on the spine, can affect internal organs, peripheral joints and vision. The Arthritis Research Campaign, estimates that on the European continent, AS prevalence ranges from 0.2 to 1 percent of the entire population. The Spondylitis Association of America estimates that between 350,000 and one million people in the U.S. suffer from Ankylosing Spondylitis.
Abbott opens biotech facility in Puerto Rico

Abbott opens biotech facility in Puerto Rico

New Crohn's disease treatment Humira promises to reduce symptoms

New Crohn's disease treatment Humira promises to reduce symptoms

FDA approves Humira (adalimumab) for Crohn's disease

FDA approves Humira (adalimumab) for Crohn's disease

NICE backs use of Enbrel and Raptiva to treat severe psoriasis

NICE backs use of Enbrel and Raptiva to treat severe psoriasis

Arthritis drug wins approval for use in children with Crohn's disease

Arthritis drug wins approval for use in children with Crohn's disease

Remicade (infliximab) gains Australian approval for treatment of early rheumatoid arthritis

Remicade (infliximab) gains Australian approval for treatment of early rheumatoid arthritis

Pfizer adds warning to Celebrex arthritis drug

Pfizer adds warning to Celebrex arthritis drug

Spinal arthritis often overlooked in children

Spinal arthritis often overlooked in children

Arthritis patients still suffer as drugs guidelines are ignored

Arthritis patients still suffer as drugs guidelines are ignored

Study suggests continuous NSAID treatment more effectively reduces X-Ray progression than intermittent treatment

Study suggests continuous NSAID treatment more effectively reduces X-Ray progression than intermittent treatment

Study comparing the efficacy of REMICADE® to Azathioprine alone and in combination With REMICADE®

Study comparing the efficacy of REMICADE® to Azathioprine alone and in combination With REMICADE®

500,000 patients have now been treated with REMICADE® worldwide

500,000 patients have now been treated with REMICADE® worldwide

Coronary stent drives Johnson & Johnson to record profits

Coronary stent drives Johnson & Johnson to record profits

FDA accepts REMICADE® (infliximab) for the treatment of early rheumatoid arthritis

FDA accepts REMICADE® (infliximab) for the treatment of early rheumatoid arthritis